ROSELLA: Phase 3 Clinical Trial for Ovarian Cancer
Key Findings and Practical Solutions
Ovarian cancer is often diagnosed late and becomes resistant to chemotherapy. The ROSELLA study aims to improve outcomes for women with platinum-resistant ovarian cancer by using relacorilant, a selective GR modulator, in combination with nab-paclitaxel.
The study includes women with recurrent, platinum-resistant, high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer who have received prior systemic anticancer therapy. Participants are randomized to receive relacorilant with nab-paclitaxel or nab-paclitaxel alone, with the primary goal of assessing progression-free survival (PFS).
Secondary endpoints include overall survival (OS), objective response rate, and safety evaluations. The study also evaluates patient-reported outcomes and clinical benefit rate at 24 weeks.
Value and Applications
Clinical trials like ROSELLA are crucial for developing effective treatments. Our AI-driven platform, DocSym, consolidates clinical protocols and research for easy access by clinicians, helping to extend the benefits of clinical trials into everyday medical practice.
In today’s healthcare environment, our mobile apps support scheduling, treatment monitoring, and telemedicine, streamlining operations and expanding digital services to improve patient care and outcomes.
By leveraging AI, clinics can enhance workflows, reduce paperwork, and improve patient outcomes. Learn more about our solutions at aidevmd.com.
